Navigation Links
Commercial Manufacturing of H1N1 'Swine Flu' Vaccine Underway
Date:6/15/2009

Approximately 100,000 doses can be manufactured per week

MERIDEN, Conn., June 15 /PRNewswire/ -- Protein Sciences Corporation (PSC) announced that today it commenced manufacturing of a vaccine to protect humans against the H1N1 "swine flu" virus. The Company estimates that it can produce 100,000 doses this week and at least 100,000 doses per week thereafter. The vaccine, called PanBlok(R), is made using PSC's proprietary baculovirus and insect cell manufacturing technology. PSC believes that PanBlok is the first and only vaccine that could be used to protect against the escalating worldwide pandemic, at least for the next few months.

Following bulk production, the vaccine will undergo routine quality tests, the longest of which will require up to one month. Thus, by mid-July the vaccine should be ready to be used in clinical trials and/or for vaccinations in countries that grant regulatory clearance.

Daniel D. Adams, Chairman, President and CEO stated, "We are in the process of transferring our proprietary manufacturing technology to facilities in other countries and we are setting up a foundation to ensure vaccine availability for U.N. member countries consistent with the commitment we made to the World Health Organization and the United Nations in Geneva, Switzerland on May 19, 2009." He added, "Using our proprietary technology, licensees could be producing vaccine in as little as two to three weeks if they are currently working with insect cells and in a few months if they are now producing monoclonal antibodies."

PSC also announced that it will begin shipping H1N1 protein for research use to customers with pre-orders. Orders may be placed on the Company's website (www.proteinsciences.com).

PSC is in late stage discussions with various parties in the United States and abroad to conduct the first human clinical trials of an H1N1 vaccine. Such studies will evaluate different doses, two dosing regimes and an adjuvanted formulation of the vaccine.

About PSC

PSC is a privately held biopharmaceutical company based in Meriden, Connecticut, whose mission it is to save lives and improve health, by effectively responding to our changing world with innovative vaccines and biopharmaceuticals. PSC uses recombinant DNA technology to make novel human and veterinary prophylactic and therapeutic vaccines and diagnostics. The active ingredients in all of the firm's products are recombinant proteins that are manufactured, using its patented protein expression technology, based upon baculovirus and insect cell technology.

PSC's lead product is FluBlok(R), a seasonal recombinant trivalent influenza vaccine consisting of influenza hemagglutinin proteins. FluBlok is manufactured without the use of eggs, is highly purified and, therefore, does not require the use of thimerosal or antibiotics, and is low in endotoxins. PSC filed a Biologics License Application for FluBlok with the FDA in April 2008 that is currently undergoing final review. PSC anticipates that FluBlok will receive FDA approval in time for the 2009/2010 influenza season.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. ADVENTRX Appoints Vice President of Commercialization
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
9. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose ... lengthy trial and error process by finding the right antidepressant faster. CNSDose ... the doctor-patient relationship through a personalized approach to treatment. , A ...
(Date:5/19/2017)... ... 2017 , ... The University City Science Center is seeking ... commercialization, and who are affiliated with the 21 partner academic and research institutions ... in its tenth round, is the first multi-institutional proof-of-concept program for the life ...
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... ... activities. The Tapas Cooking Challenge is a two-hour team-building package designed for ... menu created by Chef Jodi Abel, which include items, such as Blackened Shrimp ...
(Date:5/18/2017)... ... 17, 2017 , ... NDA Partners Chairman Carl Peck, MD , announced ... Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined the ... Health, he was former Chief Operating Officer at Anaborex, Senior VP and General Manager ...
Breaking Biology Technology:
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics ... ...
Breaking Biology News(10 mins):